Navigation Links
Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Date:11/3/2008

TREANDA Receives Second Indication this Year; Data Demonstrate High, Durable Response Rates for Patients with indolent NHL Who Have Progressed Following a Rituximab-Containing Regimen

FRAZER, Pa., Nov. 3 /PRNewswire-FirstCall/ -- Cephalon, Inc., (Nasdaq: CEPH) today announced that the U.S. Food and Drug Administration (FDA) has approved TREANDA(R) (bendamustine hydrochloride) for Injection for the treatment of patients with indolent B-cell non-Hodgkin's lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. The data supporting the FDA approval show that TREANDA is effective, has a tolerable side effect profile in patients with indolent NHL and that treatment results in a high durable response rate. In March of this year, TREANDA received approval for the treatment of patients with chronic lymphocytic leukemia, the most common form of leukemia in the United States.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/treanda/35514/

Indolent NHL, a subset of non-Hodgkin's lymphoma, is a slow growing but serious cancer of the lymphatic system that is not curable with currently available treatments. Patients with indolent NHL are prone to multiple relapses after initial therapy. According to the National Cancer Institute, an estimated 30,000 people in the United States will be diagnosed this year with indolent NHL.

"Because most patients with indolent non-Hodgkin's lymphoma eventually become resistant to existing treatments, new treatment options like TREANDA are needed to improve patient outcome," stated Dr. Bruce Cheson, Professor of Medicine at Georgetown University Hospital, Washington, D.C. and TREANDA clinical investigator. "The TREANDA pivotal trial shows that it is an effective and well-tolerated chemotherapy that offers a delay in disease progression for more than
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...s,andPressJoinEfforttoEducate ,, MEMPHIS,Tenn....nalBipolarFoundationandtheMedicAlertFoundationrece...ram,whichisnowbeingwidelyacceptedasapreventiveheal...ipolarFoundationreceivedaproclamationofendorsement...ouisianaMitchLandrieu.TheNationalBipolarFoundation...
(Date:11/25/2009)...istically significant survival benefit from adjuva...r (ER)-positive tumors had high levels of phosphor...P), according to a brief communication published o...Cancer Institute . , Approximately 50% of breast...l studies have shown that ER-alpha S118-P is requi...
(Date:11/25/2009)...s simple question has been the focus of intense re...dulates High Blood Pressure in Mice & Men, Does s...on has been the focus of intense research for many...stablished a link between a novel gene, phosducin,... as well as humans. The studies were directed by s...
(Date:11/25/2009)... arthritis, could help newly diagnosed diabetics, ...thDay News) -- A drug commonly used to treat non-H...o shows some promise in helping patients newly dia...mab (Rituxan), helped patients keep producing some... destroyed some of their pancreatic beta cells, wh...
(Date:11/25/2009)...o overlook needed care, study finds , , ...depression can worsen her child,s asthma, U.S. res... 262 black mothers and their children found that c... had more frequent asthma symptoms, while children...s frequent asthma symptoms. , The Johns Hopkins...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:New stress-related gene modulates high blood pressure in mice and men 2Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Mom's Depression May Worsen Child's Asthma 2
...arry Minnix, President & CEO, American Association...ation of the Medicare Therapy,Caps Exceptions Proc...,from Larry Minnix, President & CEO, American Asso...in having their physical and,occupational therapy ...
... The American Medical,Association (AMA) Foundation...ysician association, recently named several new bo...ers:, -- Jean Howard, Traverse City, MI, Preside...aynard, M.D., Evansville, IN, Secretary, New Mem...
...l sunscreen available at retailers nationwide and ... , ORLANDO, Fla., July 2 Caribbean Solutions,( h...een, Caribbean Sol,SolGuard SPF 25 and Kids Kare 2...ttp://www.newscom.com/cgi-bin/prnh/20080702/LAW520...
... only to childbirth as most common reason for hosp..., July 2 (HealthDay News) -- In 2006, more than 1....opulation of Dallas -- were hospitalized for pneum...mission to hospital, and treating these lung infec...
...Technologies from Los Alamos National Laboratory ... Airplanes, Cars Go On a Nanotechnology ...fics (Pink Sheets: MHTX) announced today that it h...enator,Jeff Bingaman said, "I believe the merger o...
...(July 2, 2008) - Measuring calcium deposits in the...isk in American adults, even when they are elderly...ssue of Journal of the American College of Cardio...l Center (LA BioMed), said previous studies had fo...
Other Medicine News:Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:Caribbean Sol Biodegradable Sunscreen Gets Strong Safety Rating From Environmental Working Group 2Health News:Manhattan Scientifics Acquires Metallicum, Inc. 2Health News:Manhattan Scientifics Acquires Metallicum, Inc. 3Health News:Manhattan Scientifics Acquires Metallicum, Inc. 4Health News:New study finds coronary arterial calcium scans help detect overall death risk in the elderly 2
(Date:11/25/2009)...swire-FirstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),a...vering,developingandcommercializingnoveldrugstotre...scalyearendedSeptember30,2009.AtSeptember30,2009Ph...hortterminvestments. ,, PipelineUpdateand2009H..., InlateNovember2009,anindependentDataMonitorin...
(Date:11/25/2009)...,Nov.25/PRNewswire/-- FromNovember16-18,Phonak,the...esentedthesecondeditionoftheHearingCareforAdultsCo...tion.Theconferencebroughttogetherleadingexpertsina...inicianswhoworkeverydaywitholderpeoplewithhearingl...latestresearchandtrendsinhearingcareforolderpeople...
(Date:11/25/2009)...ewswire/--TheFDAgrantedtraditionalapprovalforINTEL...setranscriptaseinhibitor(NNRTI).INTELENCEistheonly...encedadultswhoareexperiencingvirologicfailurewithH...l(ARV)agents.Thetraditionalapprovalisbasedon48-wee...TELENCEiscurrentlymarketedintheU.S.byTibotecTherap...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Netech Corporation Announces the Release of IPA 2000 Infusion Pump Analyzer for Fast and Accurate Testing of All Infusion Pumps 14891 1Netech Corporation Announces the Release of IPA 2000 Infusion Pump Analyzer for Fast and Accurate Testing of All Infusion Pumps 14891 2Bay Area Plastic Surgeon Reaches Out to Patients with New State of the Art Website 61595 1Bay Area Plastic Surgeon Reaches Out to Patients with New State of the Art Website 61595 2Bay Area Plastic Surgeon Reaches Out to Patients with New State of the Art Website 61595 3Bull 26apos 3Bs Eye 3A AHF 26apos 3Bs 26amp 3B 238220 3BNo Judgemental Bullsh t 26amp 3B 238221 3B HIV Testing Campaign Hits the Mark 61590 1Bull 26apos 3Bs Eye 3A AHF 26apos 3Bs 26amp 3B 238220 3BNo Judgemental Bullsh t 26amp 3B 238221 3B HIV Testing Campaign Hits the Mark 61590 2Bull 26apos 3Bs Eye 3A AHF 26apos 3Bs 26amp 3B 238220 3BNo Judgemental Bullsh t 26amp 3B 238221 3B HIV Testing Campaign Hits the Mark 61590 3
...one Systems Incorporated,(Nasdaq: IMCL ) and Bris...nced,that the U.S. Food and Drug Administration (F...ximab) product labeling to include overall surviva...r inhibitor,(EGFR)-expressing metastatic colorecta...notecan- and oxaliplatin-based regimens. The appr...
...cond Cerimon Product Candidate to Enter Clinical ...SAN FRANCISCO, Oct. 2 Cerimon Pharmaceuticals,Inc...ical study of a novel,diclofenac sodium patch, the...e safety, tolerability, and systemic pharmacokinet...odium, a non-steroidal anti-inflammatory,drug (NSA...
Other Medicine Technology:Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 2Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch 3
Liquichek D-dimer Control
... use in assessing compliance with specimen handlin...f custody, for Federal Workplace Drug Testing Prog...ealth Services Administration (SAMHSA), Health and... agencies. These samples are confirmed negative fo...
Liquichek Reticulocyte Stain
Seroconversion and Antigen Panel Chart
Medicine Products: